Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Drug Profile

Meningococcal vaccine groups A C Y W-135 conjugate - Novartis

Alternative Names: GSK3536820A; MCV4 vaccine; MenACWY-CRM; Menhycia; Menveo; Multivalent ACWY vaccine candidate - Novartis

Latest Information Update: 01 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer GSK; Novartis; Tianjin CanSino Biotechnology
  • Class Conjugate vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Meningococcal infections

Most Recent Events

  • 26 Jan 2024 CanSino Biologics plans a phase III trial for Meningococcal infections (Prevention) (IM, Injection), in March 2024 (NCT06226714)
  • 14 Nov 2023 CanSino Biologics plans a phase III trial for Meningococcal infections in Indonesia (IM, Injection) in December 2023 (NCT06131554)
  • 31 Aug 2023 Tianjin CanSino Biotechnology plans a phase IIIb trial for Meningococcal infections (In children, Prevention) (IM) (NCT06011200)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top